Improvement in Cognition by α7 Nicotinic Acetylcholine Receptor Partial Agonist APN1125 in Preclinical Models as a Prologue to Clinical Development

被引：0
|
作者：
Detke, Michael J. [1 ,2 ]
Stevens, Karen E. [3 ]
Koelsch, Gerald [4 ]
Anderson, Paul C. [4 ]
Meltzer, Leonard T. [5 ]
Yoshimura, Ryan F. [6 ]
Bilcer, Geoffrey [7 ]
Ng, John [8 ]
Ng, Raymond [8 ]
Gee, Kelvin W. [6 ]
Kelly, Terence A. [7 ]
机构：
[1] CoMentis, Clin, San Francisco, CA USA
[2] Indiana Univ, San Francisco, CA USA
[3] Univ Colorado, Psychiat, Denver, CO 80202 USA
[4] CoMentis & Alpharmagen, Biol, San Francisco, CA USA
[5] L Meltzer CNS Consulting, Biol, Ann Arbor, MI USA
[6] Alpharmagen & Anvyl, Biol, San Francisco, CA USA
[7] CoMentis & Alpharmagen, Chem, San Francisco, CA USA
[8] CoMentis & Alpharmagen, CMC, San Francisco, CA USA
来源：
BIOLOGICAL PSYCHIATRY | 2015年 / 77卷 / 09期
关键词：
nicotinic; cognition; schizophrenia;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
738
引用
收藏
页数：1
相关论文
共 42 条
  • [31] SSR180711, a novel selective α7 nicotinic receptor partial agonist:: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia
    Pichat, Philippe
    Bergis, Olivier E.
    Terranova, Jean-Paul
    Urani, Alexandre
    Duarte, Christine
    Santucci, Vincent
    Gueudet, Christiane
    Voltz, Carole
    Steinberg, Regis
    Stemmelin, Jeanne
    Oury-Donat, Florence
    Avenet, Patrick
    Griebel, Guy
    Scatton, Bernard
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (01) : 17 - 34
  • [32] SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia
    Philippe Pichat
    Olivier E Bergis
    Jean-Paul Terranova
    Alexandre Urani
    Christine Duarte
    Vincent Santucci
    Christiane Gueudet
    Carole Voltz
    Régis Steinberg
    Jeanne Stemmelin
    Florence Oury-Donat
    Patrick Avenet
    Guy Griebel
    Bernard Scatton
    Neuropsychopharmacology, 2007, 32 : 17 - 34
  • [33] Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia:: Development of a selective α7 nicotinic acetylcholine receptor agonist strategy
    Deutsch, Stephen L.
    Rosse, Richard B.
    Schwartz, Barbara L.
    Schooler, Nina R.
    Gaskins, Brooke L.
    Long, Katrice D.
    Mastropaolo, John
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (02) : 147 - 151
  • [34] An Alpha-7 Nicotinic Partial Agonist, EVP-5124, Produces Positive Effects on Cognition, Clinical Function, and Negative Symptoms in Patients with Chronic Schizophrenia on Stable Antipsychotic Therapy
    Hilt, Dana C.
    NEUROTHERAPEUTICS, 2012, 9 (03) : 678 - 679
  • [35] AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in parkinsonian monkeys
    Di Paolo, Therese
    Gregoire, Laurent
    Feuerbach, Dominik
    Elbast, Walid
    Weiss, Markus
    Gomez-Mancilla, Baltazar
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (11) : 1119 - 1123
  • [36] A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY OF ENCENICLINE, AN A7 NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, FOR COGNITIVE IMPAIRMENT IN PATIENTS WITH SCHIZOPHRENIA
    Lombardo, Ilise
    Dgetluck, Nancy
    Koenig, Gerhard
    Loewen, Gordon
    Hilt, Dana
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S321 - S321
  • [37] Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
    O'Donnell, Christopher J.
    Rogers, Bruce N.
    Bronk, Brian S.
    Bryce, Dianne K.
    Coe, Jotham W.
    Cook, Karen K.
    Duplantier, Allen J.
    Evrard, Edelweiss
    Hajos, Mihaly
    Hoffmann, William E.
    Hurst, Raymond S.
    Maklad, Noha
    Mather, Robert J.
    McLean, Stafford
    Nedza, Frank M.
    O'Neill, Brian T.
    Peng, Langu
    Qian, Weimin
    Rottas, Melinda M.
    Sands, Steven B.
    Schmidt, Anne W.
    Shrikhande, Alka V.
    Spracklin, Douglas K.
    Wong, Diane F.
    Zhang, Andy
    Zhang, Lei
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (03) : 1222 - 1237
  • [38] Unichiral 2-(2′-Pyrrolidinyl)-1,4-benzodioxanes: the 2R,2′S Diastereomer of the N-Methyl-7-hydroxy Analogue Is a Potent α4β2-and α6β2-Nicotinic Acetylcholine Receptor Partial Agonist
    Bolchi, Cristiano
    Gotti, Cecilia
    Binda, Matteo
    Fumagalli, Laura
    Pucci, Luca
    Pistillo, Francesco
    Vistoli, Giulio
    Valoti, Ermanno
    Pallavicini, Marco
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (21) : 7588 - 7601
  • [39] N-[5-(5-Fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A Medicinal Chemistry Effort toward an α7 Nicotinic Acetylcholine Receptor Agonist Preclinical Candidate
    Zanaletti, Riccardo
    Bettinetti, Laura
    Castaldo, Cristiana
    Ceccarelli, Ilaria
    Cocconcelli, Giuseppe
    Comery, Thomas A.
    Dunlop, John
    Genesio, Eva
    Ghiron, Chiara
    Haydar, Simon N.
    Jow, Flora
    Maccari, Laura
    Micco, Iolanda
    Nencini, Arianna
    Fratelli, Carmela
    Scali, Carla
    Turlizzi, Elisa
    Valacchi, Michela
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 10277 - 10281
  • [40] (R)-3′-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5′-oxazolidin]-2′-one, a novel and potent α7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties
    Tatsumi, Ryo
    Fujio, Masakazu
    Takanashi, Shin-ichi
    Numata, Atsushi
    Katayama, Jiro
    Satoh, Hiroyuki
    Shiigi, Yasuyuki
    Maeda, Jun-Ichi
    Kuriyama, Makoto
    Horikawa, Takashi
    Murozono, Takahiro
    Hashimoto, Kenji
    Tanaka, Hiroshi
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (14) : 4374 - 4383
12345